RadNet delivered a clean headline beat in the third quarter. Adjusted earnings of $0.30 per share topped the $0.21 consensus by 42.9% and rose 50.0% from a year ago. Revenue of $638.26 million grew 22.1% but beat expectations by only 0.1%. Management raised Imaging Center guidance for the third consecutive quarter and announced the pending OnRad acquisition, its most consequential strategic move in some time. That is the central tension: the core imaging business keeps outrunning its own forecasts, while Digital Health, the segment meant to carry the long-term narrative, slowed sharply on a sequential basis just as its full-year targets came to depend on a large fourth-quarter ramp.

The quality of the beat deserves scrutiny. GAAP net income attributable to RadNet fell to $4.2 million, or $0.05 per share, from $5.4 million, or $0.07. Roughly $28.3 million of pre-tax adjustments separate the GAAP and adjusted figures. These include an $8.3 million non-cash contingent consideration charge, $7.3 million of Digital Health intangibles amortization, a $5.4 million equipment disposal loss and $2.8 million in legal settlements. The prior-year adjusted figure was also restated to add back equipment losses and Digital Health amortization, so the 50% growth rate rests on a recently redefined baseline. To management's credit, the $7.5 million gain on contributing centers to joint ventures was stripped out rather than kept. Noncontrolling interests also took a larger share of profits, $15.0 million versus $8.5 million, which reflects the growing joint-venture model.

Operationally, the imaging engine is the strongest part of the story:

• Adjusted EBITDA reached a record $105.0 million, up 23.8%, with margin edging up to 16.5%.
• Imaging Center EBITDA rose 25.3%.
• Aggregate advanced imaging volumes grew 19.9%, and PET/CT jumped 30.4%.
• Advanced imaging reached 30.6% of procedures, continuing a steady climb from 28.6% in the fourth quarter of 2025.

Growth is steady rather than accelerating. Revenue growth matched the first quarter's 22.1%, but EBITDA growth has cooled from 36.3% in the first quarter. Same-center advanced imaging volume growth eased to 8.9% from 9.6% in the second quarter, and total same-center procedures rose just 3.2%. Much of the headline growth is therefore coming from acquisitions, de novo centers (about ten expected this year versus seven planned) and mix.

Digital Health is where bears have legitimate ammunition:

• Segment revenue rose 32.6% year over year but only 1.5% sequentially, compared with 56.5% and 11.4% in the second quarter.
• Segment EBITDA of $3.0 million remained below last year's $3.5 million.
• ARR growth slowed to about 7% quarter over quarter.

Management reaffirmed $135 million to $145 million in full-year segment revenue. With $94.5 million booked through nine months, that requires more than $40 million in the fourth quarter, roughly a 20% sequential jump. Management cited seasonality, iCAD cloud-migration headwinds and implementation capacity constraints. Bookings do support eventual recovery. Third-quarter contract value was about $71 million, including a $53 million teleradiology enterprise deal, the pipeline topped $300 million, and Gleamer reached $31 million in ARR a quarter ahead of target. Converting that backlog into recognized revenue is the open question.

OnRad changes the investment setup. The deal is expected to add $190 million to $200 million in revenue and $60 million to $65 million in EBITDA in its first year, at margins above 30%. It would create a third reporting segment and a hospital channel for Digital Health. The price, however, is substantial: $350 million in cash, 5 million shares, and an earn-out at 15 times 2027 EBITDA above $56 million. Integration risk is real. The balance sheet looks able to absorb it, with $750.6 million in cash and leverage down to 1.66x from 1.8x, although notes payable have risen meaningfully this year to fund acquisitions. Other risks include:

• The 2027 Medicare final rule, now an estimated $5 million headwind versus under $1 million under the proposed rule.
• Persistent technologist and radiologist wage pressure.
• Guidance that implies a softer fourth-quarter imaging margin than the third quarter.
• An outlook that, despite the raise, still sits below what the Street had been modeling.

Investor sentiment improved from -0.08 to +0.08 ahead of the report. That is a meaningful swing from mildly skeptical to mildly constructive, but hardly euphoric. Shares entered the release at $76, up 4.1% since the open after the August report and 16.4% above the 200-day moving average. The stock had pulled back 7.2% from an inter-earnings high of $81.87 set on November 5, after rebounding from an October low of $66.23. The Earnings Whispers trend readings are broadly positive, consistent with a stock that has been rewarded for execution but had already cooled from its peak before the print.

The bottom line is that RadNet's core imaging business keeps beating its own plan, and OnRad adds a sizable, higher-margin growth leg. Investors should still separate adjusted earnings strength from flat GAAP profits, and watch whether Digital Health can deliver the steep fourth-quarter revenue ramp its reaffirmed guidance demands.